Patent law http://www.globalpost.com/taxonomy/term/32990/all en Google fires back at British Telecom in patent row http://www.globalpost.com/dispatch/news/afp/130214/google-fires-back-at-british-telecom-patent-row <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Google fired back at British telecom titan BT Group in US and British courts Wednesday, escalating a year-old patent battle.</p> <p>"We have always seen litigation as a last resort, and we work hard to avoid lawsuits," Google said in a statement.</p> <p>"But, BT has brought several meritless patent claims against Google and our customers -- and they've also been arming patent trolls. When faced with these kinds of actions, we will defend ourselves."</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130214/google-fires-back-at-british-telecom-patent-row" target="_blank">read more</a></p> British telecom BT Group Google Intellectual property law Patent law Patent troll Technology AFP Thu, 14 Feb 2013 19:31:15 +0000 5755974 at http://www.globalpost.com Brazil inventor struggles to collect royalties http://www.globalpost.com/dispatch/news/afp/130303/brazil-inventor-struggles-collect-royalties <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Fifteen years after he patented caller ID technology, Brazilian inventor Nelio Jose Nicolai is no millionaire.</p> <p>Quite the opposite: out of work since 1984, the co-inventor of the ubiquitous tool is still fighting to collect royalties.</p> <p>"This revolutionized cellular telephony," Nicolai proudly told AFP of his BIMA technology, recalling the rapturous welcome it received in Canada and the United States.</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130303/brazil-inventor-struggles-collect-royalties" target="_blank">read more</a></p> Electronic engineering Jose Nicolai Patent law Telephony AFP Sun, 03 Mar 2013 10:30:37 +0000 5772026 at http://www.globalpost.com Insight - Nation-states enter contentious patent-buying business http://www.globalpost.com/dispatch/news/thomson-reuters/130320/insight-nation-states-enter-contentious-patent-buying-business <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Dan Levine and Miyoung Kim</p> <p>SAN FRANCISCO/SEOUL (Reuters) - Patent competition in the United States is usually a fierce arena for private companies, but now the South Korean and French governments are suiting up.</p> <p>Both countries have launched patent-acquisition companies, with the goal of helping domestic technology firms and possibly making some money in the process. China and Japan are making moves into the business too.</p> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130320/insight-nation-states-enter-contentious-patent-buying-business" target="_blank">read more</a></p> Business Intellectual property law Monopoly Patent law Technology Thomson Reuters Wed, 20 Mar 2013 07:15:17 +0000 5788452 at http://www.globalpost.com Big Pharma in nervous wait for India verdict on Glivec patent http://www.globalpost.com/dispatch/news/thomson-reuters/130327/big-pharma-nervous-wait-india-verdict-glivec-patent <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Kaustubh Kulkarni</p> <p>MUMBAI (Reuters) - Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling next week that could have broad consequences for their ability to sell lucrative patented medicines in the country.</p> <p>India's Supreme Court is due to decide on April 1 whether or not an amended form of Swiss giant Novartis AG's &lt;NOVN.VX&gt; cancer treatment Glivec deserves a patent in the country.</p> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130327/big-pharma-nervous-wait-india-verdict-glivec-patent" target="_blank">read more</a></p> Business Hospitality Law Patent law Pharmaceutical sciences Politics Social Issues Technology Thomson Reuters Wed, 27 Mar 2013 07:30:04 +0000 5795020 at http://www.globalpost.com India top court to rule in landmark drug patent case http://www.globalpost.com/dispatch/news/afp/130331/india-top-court-rule-landmark-drug-patent-case <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's top court is set to rule Monday on a patent challenge by Swiss pharmaceutical giant Novartis that activists say threatens access to cheap generic versions of life-saving drugs in poor nations.</p> <p>Generic drug firms in India -- long known as the "pharmacy to the developing world" -- have been a major supplier of copycat medicines to treat diseases such as cancer, TB and AIDS for those who cannot afford expensive branded versions.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130331/india-top-court-rule-landmark-drug-patent-case" target="_blank">read more</a></p> Business Hospitality Law Patent law Pharmaceutical sciences Pharmacology Politics Social Issues AFP Sun, 31 Mar 2013 07:00:27 +0000 5797951 at http://www.globalpost.com India top court to deliver key drug patent ruling http://www.globalpost.com/dispatch/news/afp/130331/india-top-court-deliver-key-drug-patent-ruling <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's Supreme Court is set to rule Monday on a patent challenge by Swiss drug giant Novartis that activists say threatens access to cheap generic versions of life-saving drugs in developing nations.</p> <p>The landmark case -- watched closely by global drug firms and patient groups -- involves an updated version of Novartis' blockbuster cancer drug Glivec, for which the company has fought a seven-year legal battle to win patent protection.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130331/india-top-court-deliver-key-drug-patent-ruling" target="_blank">read more</a></p> Business Hospitality Law Patent law Pharmaceutical sciences Pharmaceuticals policy Politics Social Issues AFP Sun, 31 Mar 2013 21:30:47 +0000 5798259 at http://www.globalpost.com Novartis loses landmark India cancer drug patent case http://www.globalpost.com/dispatch/news/thomson-reuters/130401/indias-top-court-dismisses-novartis-petition-glivec-patent <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Kaustubh Kulkarni and Suchitra Mohanty</p> <p>MUMBAI/NEW DELHI (Reuters) - India's top court dismissed Swiss drug maker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130401/indias-top-court-dismisses-novartis-petition-glivec-patent" target="_blank">read more</a></p> BSE Sensex Business Cipla Health Hospitality Imatinib Indian Patent Office Labor Law Novartis Patent law Patent offices Pharmaceutical industry Pharmaceutical sciences Politics Social Issues Technology Thomson Reuters Mon, 01 Apr 2013 06:00:03 +0000 5798404 at http://www.globalpost.com India's top court backs generics in key drug patent ruling http://www.globalpost.com/dispatch/news/afp/130401/indias-top-court-backs-generics-key-drug-patent-ruling <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis, in a landmark ruling that activists say will protect access to cheap generic versions of drugs in developing nations.</p> <p>Novartis fought a seven-year legal battle to gain patent protection for an updated version of its blockbuster cancer drug Glivec, arguing that the compound was a significant improvement because it is more easily absorbed by the body.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130401/indias-top-court-backs-generics-key-drug-patent-ruling" target="_blank">read more</a></p> Business Hospitality Law Patent law Pharmaceutical sciences Pharmaceuticals policy Politics Social Issues AFP Mon, 01 Apr 2013 06:16:35 +0000 5798413 at http://www.globalpost.com India's top court backs generics in key drug patent ruling http://www.globalpost.com/dispatch/news/afp/130401/indias-top-court-backs-generics-key-drug-patent-ruling-0 <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic drugs and save lives in developing nations.</p> <p>Novartis fought a seven-year legal battle to gain patent protection for an updated version of its blockbuster cancer drug Glivec, arguing that the compound was a significant improvement because it is more easily absorbed by the body.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130401/indias-top-court-backs-generics-key-drug-patent-ruling-0" target="_blank">read more</a></p> Business Hospitality Law Patent law Pharmaceutical sciences Politics Social Issues AFP Mon, 01 Apr 2013 08:30:10 +0000 5798462 at http://www.globalpost.com India's top court backs generics in key drug patent ruling http://www.globalpost.com/dispatch/news/afp/130401/indias-top-court-backs-generics-key-drug-patent-ruling-1 <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect cheap generic drugs and save lives in developing nations.</p> <p>Novartis fought a seven-year legal battle to gain patent protection for an updated version of its blockbuster leukaemia drug Glivec, arguing the compound was a significant improvement because it is more easily absorbed by the body.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130401/indias-top-court-backs-generics-key-drug-patent-ruling-1" target="_blank">read more</a></p> Business Hospitality Law Patent law Pharmaceutical sciences Pharmaceuticals policy Politics Social Issues AFP Mon, 01 Apr 2013 11:30:53 +0000 5798526 at http://www.globalpost.com India's top court backs generics in key drug patent ruling http://www.globalpost.com/dispatch/news/afp/130401/indias-top-court-backs-generics-key-drug-patent-ruling-2 <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling activists say will allow continued supply of cheap generic drugs and save lives in poorer nations.</p> <p>Novartis fought a seven-year legal battle to gain patent protection for an updated version of its blockbuster leukaemia drug Glivec, arguing the compound was a significant improvement because it is more easily absorbed by the body.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130401/indias-top-court-backs-generics-key-drug-patent-ruling-2" target="_blank">read more</a></p> Business Hospitality Law Patent law Pharmaceutical sciences Politics Social Issues AFP Mon, 01 Apr 2013 14:45:42 +0000 5798612 at http://www.globalpost.com Novartis loses landmark India cancer drug patent case http://www.globalpost.com/dispatch/news/asianet/130403/novartis-loses-landmark-india-cancer-drug-patent-case <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Asianet </div> </div> </div> <!--paging_filter--><p></p><P> India's top court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics, APA reports quoting Reuters.</p><P>The decision sets a benchmark for intellectual property cases in India, where many patented drugs are unaffordable for most of its 1.2 billion people, and does not bode well for foreign firms engaged in ongoing disputes in India, including Pfizer Inc and Roche Holding AG, analysts said.</p><P>It cements the role of local</p> <p><a href="http://www.globalpost.com/dispatch/news/asianet/130403/novartis-loses-landmark-india-cancer-drug-patent-case" target="_blank">read more</a></p> BSE Sensex Business Health Hospitality Labor Law Novartis Patent law Politics Social Issues Technology Asianet Wed, 03 Apr 2013 17:46:20 +0000 Asianet 5800843 at http://www.globalpost.com India defends rejection of Novartis patent bid http://www.globalpost.com/dispatch/news/afp/130408/india-defends-rejection-novartis-patent-bid <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>An Indian court was fully justified to reject a patent bid by Swiss drug giant Novartis last week, India's trade and industry minister insisted in Geneva on Monday, defending the country's generic drug business.</p> <p>"The reasons for the denial .. are absolutely justified under the law," Anand Sharma told reporters following a ceremony marking his country's accession to the Madrid Protocol, an international trademark system.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130408/india-defends-rejection-novartis-patent-bid" target="_blank">read more</a></p> Business Hospitality Law Novartis Patent law Pharmaceutical sciences Politics Social Issues AFP Mon, 08 Apr 2013 15:32:14 +0000 5805662 at http://www.globalpost.com Inventions, practical and oddball, showcased at Geneva fair http://www.globalpost.com/dispatch/news/afp/130410/inventions-practical-and-oddball-showcased-at-geneva-fair <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>The impeccably-dressed South Korean flipped a tyre sideways, and with a deft sweep snapped a curious, pastel-shaded device onto the hub.</p> <p>"Fitted in seconds," he said with a flourish, drawing nods of approval from Swiss onlookers all too used to their annual battle to preserve their fingers as they fix snow chains during the Alpine winter.</p> <p>Welcome to the International Exhibition of Inventions in Geneva which bills itself as the biggest of its kind in the world.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130410/inventions-practical-and-oddball-showcased-at-geneva-fair" target="_blank">read more</a></p> Arts Patent law Technology Transport AFP Thu, 11 Apr 2013 03:16:25 +0000 5810088 at http://www.globalpost.com India concerned FTA with EU might affect public health: paper http://www.globalpost.com/dispatch/news/asianet/130415/india-concerned-fta-eu-might-affect-public-health-paper <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Asianet </div> </div> </div> <!--paging_filter--><p></p><P> India is concerned that a free trade agreement with the European Union could jeopardize the country's pubic health, as such an agreement with EU would lead to a restriction of supply of generic medicines in the country and abroad as well, according to local media reports.</p><P>There are genuine concerns that the Free Trade Agreement, which India is finalizing with the European Union, can prove detrimental to health equity, said local daily The Tribune on Saturday.</p><P>"Supply of low cost generic medicines to patients within the country and in less developed nations should not be threate</p> <p><a href="http://www.globalpost.com/dispatch/news/asianet/130415/india-concerned-fta-eu-might-affect-public-health-paper" target="_blank">read more</a></p> Business European Union Patent law Pharmaceutical sciences Asianet Mon, 15 Apr 2013 18:56:56 +0000 Asianet 5816360 at http://www.globalpost.com